Wilmington, United States
InSilicoTrials, founded in 2016, is a pioneering technology company at the forefront of life sciences innovation. Operating under the slogan "Innovating Life Sciences," the company is transforming drug development by utilizing AI-driven simulations. Headquartered in the United States, InSilicoTrials provides pharmaceutical and biotech firms with a comprehensive platform that features an extensive library of computational models.
The platform's capabilities allow companies to simulate drug interactions and predict outcomes, significantly hastening the discovery of new treatments. Leveraging digital patient twin technology and advanced AI algorithms, InSilicoTrials offers a more streamlined and cost-effective method for drug development, minimizing the dependence on early-stage human trials and enhancing decision-making throughout the process.
The company's innovative approach garnered a $2.00M grant investment from Horizon 2020 on 01 November 2020, indicating strong confidence in its potential to overhaul traditional pharmaceutical methodologies.
-logo.jpg){kind=logo}
